Free Daily Podcast Summary
BiotechTV - News: Daily Summaries Delivered
by BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 5 days ago35 min
ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs
The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.
- 5 days ago13 min
ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications
Dr. Mark Goldsmith of Revolution Medicines describes the benefit seen by advanced patients who received the pancreatic cancer pill daraxonrasib vs those in a control group of investigator's choice standard-of-care chemotherapy, and he discusses the medicine's side effect profile. Plus, next steps for this treatment in pancreatic cancer and beyond.
- May 5, 202616 min
London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors
Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR program is preparing to go into the clinic.
- Apr 22, 202622 min
Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process
Philip Astley-Starke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.
- Apr 22, 202622 min
Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination
CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases.
- Apr 21, 202616 min
Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip
Co-Founder & CEO Michel Maharbiz describes the idea behind this brain-computer interface (BCI), which is not yet in human trials. While cautioning that much work and learning lies ahead, he sees the possibility that such a system could also improve a patient's rehab and might potentially have further uses in diseases of cognitive decline.
- Apr 21, 202642 min
Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more
He describes his work in tropical disease, and how climate change has been elevating it in areas like the Gulf Coast of the United States. Plus, the importance of elevating scientists, what he has found works best for communicating with the public, and why he disagrees with the idea of 'hunkering down' until a day that science funding might rebound in the U.S..
- Apr 20, 202613 min
Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar
He shares his thoughts on the data, the competitive profile of this IL-2 Treg therapy vs JAK inhibitors, and how the overall platform looks for other I&I conditions.
About BiotechTV - News
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from BiotechTV - News in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's BiotechTV - News daily summary?
It's a free AI-powered email that summarizes new episodes of BiotechTV - News as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the BiotechTV - News podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official BiotechTV - News product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by BiotechTV.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does BiotechTV - News release new episodes?
BiotechTV - News publishes daily. Our AI generates a summary within hours of each new episode.
What topics does BiotechTV - News cover?
BiotechTV - News covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting BiotechTV - News summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.